Document Detail


Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.
MedLine Citation:
PMID:  20382695     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Taspoglutide is a novel analog of human glucagon-like peptide-1 [hGLP-1(7-36)NH2] in clinical development for the treatment of type 2 diabetes. Taspoglutide contains alpha-aminoisobutyric acid substitutions replacing Ala(8) and Gly(35) of hGLP-1(7-36)NH2. The binding affinity [radioligand binding assay using [(125)I]hGLP-1(7-36)NH2], potency (cAMP production in CHO cells stably overexpressing hGLP-1 receptor), and in vitro plasma stability of taspoglutide compared with hGLP-1(7-36)NH2 have been evaluated. Effects on basal and glucose-stimulated insulin secretion were determined in vitro in INS-1E cells and in vivo in normal rats. Taspoglutide has comparable affinity (affinity constant 1.1 +/- 0.2 nm) to the natural ligand (affinity constant 1.5 +/- 0.3 nm) for the hGLP-1 receptor and exhibits comparable potency in stimulating cAMP production (EC(50) Taspo 0.06 nm and EC(50) hGLP-1(7-36)NH2 0.08 nm). Taspoglutide exerts insulinotropic action in vitro and in vivo and retains the glucoincretin property of hGLP-1(7-36)NH2. Stimulation of insulin secretion is concentration dependent and evident in the presence of high-glucose concentrations (16.7 mm) with a taspoglutide concentration as low as 0.001 nm. Taspoglutide is fully resistant to dipeptidyl peptidase-4 cleavage (during 1 h incubation at room temperature with purified enzyme) and has an extended in vitro plasma half-life relative to hGLP-1(7-36)NH2 (9.8 h vs. 50 min). In vitro, taspoglutide does not inhibit dipeptidyl peptidase-4 activity. This study provides the biochemical and pharmacological basis for the sustained plasma drug levels and prolonged therapeutic activity seen in early clinical trials of taspoglutide. Excellent stability and potency with substantial glucoincretin effects position taspoglutide as a promising new agent for treatment of type 2 diabetes.
Authors:
Elena Sebokova; Andreas D Christ; Haiyan Wang; Sabine Sewing; Jesse Z Dong; John Taylor; Michael A Cawthorne; Michael D Culler
Related Documents :
6526265 - Use of the artificial beta cell (abc) in the assessment of peripheral insulin sensitivi...
2687145 - Postreceptor regulation of insulin action in primary cultures of rat hepatocytes by ora...
701385 - Responsiveness to insulin is a dominant characteristic in somatic cell hybrids.
18287215 - Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 ...
11128745 - Maternal and fetal serum lipid and lipoprotein concentrations and compositions in type ...
3830845 - Survey of foot deformities among 166 geriatric inpatients.
Publication Detail:
Type:  Journal Article     Date:  2010-04-09
Journal Detail:
Title:  Endocrinology     Volume:  151     ISSN:  1945-7170     ISO Abbreviation:  Endocrinology     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-21     Completed Date:  2010-06-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375040     Medline TA:  Endocrinology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2474-82     Citation Subset:  AIM; IM    
Affiliation:
F. Hoffmann-La Roche AG, PRDM, Building 68/310 Grenzacherstrasse 124, CH-4070 Basel, Switzerland. elena.sebokova@roche.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, CD26 / metabolism
CHO Cells
Cell Line, Tumor
Cricetinae
Cricetulus
Cyclic AMP / metabolism
Drug Stability
Enzyme-Linked Immunosorbent Assay
Glucagon-Like Peptide 1 / analogs & derivatives*
Humans
Insulin / metabolism
Peptides / blood,  chemistry,  pharmacokinetics,  pharmacology*
Protein Binding
Rats
Rats, Sprague-Dawley
Receptors, Glucagon / metabolism
Chemical
Reg. No./Substance:
0/Peptides; 0/Receptors, Glucagon; 0/glucagon-like peptide receptor; 0/taspoglutide; 11061-68-0/Insulin; 60-92-4/Cyclic AMP; 89750-14-1/Glucagon-Like Peptide 1; EC 3.4.14.5/Antigens, CD26; EC 3.4.14.5/DPP4 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adipocyte-Derived Microvesicles Are Associated with Multiple Angiogenic Factors and Induce Angiogene...
Next Document:  Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heighte...